Skip to main content
RVPH logo

RVPH · Reviva Pharmaceuticals Holdings, Inc. · Documents

Track RVPH — free
$0.39 +0.04 (+10.76%) At close · May 14
Market Cap
$6.33M
Shares
13.11M
Volume · May 14 742.02K Avg daily vol (48 sessions) 985.8K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $19.86M 10-K filed Mar 30, 2026 Quarterly report New FY2026 Q3 Net loss $2.3M 10-Q filed Nov 13, 2026 Latest results New Net loss $2.3 million; FDA feedback expected Q4 2026 8-K filed Nov 13, 2026
2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash insufficient for 12 months, raising going-concern doubt

Reviva Pharmaceuticals Holdings, Inc. said cash and cash equivalents were approximately $17.5 million as of September 30, 2026, but current cash would not satisfy operating needs for 12 months, raising substantial doubt about its ability to continue as a going concern.

Net loss $2.3M
Read from the first part of this long document
4 source passages
Reviva Pharmaceuticals Holdings, Inc. (together with its consolidated subsidiaries, the “Company” or "Reviva") is a late-stage pharmaceutical company developing new therapies that seek to address unmet medical needs in the areas of central nervous system ("CNS"), inflammatory and cardiometabolic diseases. The Company has incurred losses since inception and as of September 30, 2026, the Company had a working capital surplus of approximately $13.1 million, an accumulated deficit of approximately $192.1 million and cash and cash equivalents on hand of approximately $17.5 million. The Company’s current cash on hand is not sufficient to satisfy its operating cash needs for the 12 months from the filing of this Quarterly Report on Form 10-Q. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the consolidated financial statements are issued. Open the document at this passage
Nov 13
Current report 8-K Events of Nov 12
Net loss $2.3 million; FDA feedback expected Q4 2026

Reviva reported a net loss of approximately $2.3 million, or $0.17 per share, for the three months ended September 30, 2026. FDA feedback on brilaroxazine is expected Q4 2026, and RECOVER-2 enrollment is targeted for 1H 2027, subject to additional financing.

Financial results, Regulation FD disclosure
4 source passages
Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the third quarter ended September 30, 2026 and summarized recent business highlights. The Company reported a net loss of approximately $2.3 million, or $0.17 per share, for the three months ended September 30, 2026, compared to a net loss of approximately $4.0 million, or $1.09 per share, for the three months ended September 30, 2025. FDA feedback on use of a new formulation of brilaroxazine in RECOVER-2 trial expected Q4 2026 Bioequivalence study on the new formulation of brilaroxazine expected to initiate in Q1 2027. Patient enrollment in the RECOVER-2 Phase 3 trial expected to initiate in 1H 2027, subject to receipt of additional financing Open the document at this passage
Nov 9
Annual report to holders ARS
One-for-twenty reverse split effective March 9, 2026

Reviva Pharmaceuticals Holdings, Inc. effected a one-for-twenty reverse stock split effective March 9, 2026, then closed a public offering on March 20, 2026 that generated approximately $8.9 million in net proceeds.

Read from the first part of this long document
4 source passages
Reviva Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) The Reverse Stock Split became effective in accordance with the terms of the amendment at 12:01 a.m. Eastern Time on March 9, 2026 under a new CUSIP number, 76152G209. On March 20, 2026, we closed a public offering (the “March 2026 Public Offering”) The net proceeds to us from the March 2026 Public Offering were approximately $8.9 million, after deducting Placement Agent fees and expenses and other offering expenses payable by us. Open the document at this passage
Nov 9
Proxy statement DEF 14A Meeting Dec 18, 2026
Stockholders to vote on reverse split and director slate

At its December 18, 2026 meeting, Reviva Pharmaceuticals Holdings, Inc. will seek five director elections and approval of a reverse split from one-for-two (1:2) to one-for-one hundred (1:100). The board could implement it by December 31, 2027 without further approval.

Read from the first part of this long document
3 source passages
This proxy statement contains information related to the Annual Meeting of Stockholders (the “Annual Meeting”) of Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “Reviva”, “we”, “us” or “our”) to be held on Friday, December 18, 2026 at 11:00 a.m. Pacific Time. To elect five director nominees to serve as directors until the next annual meeting of stockholders; To adopt and approve an amendment to the Certificate of Incorporation to effect a reverse stock split of the Company’s issued shares of common stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-one hundred (1:100), at any time prior to December 31, 2027, subject to the Board of Directors’ determination, in its sole discretion, whether or not to implement the reverse stock split and, if so, at what specific ratio within the foregoing range, without further approval or authorization of the Company’s stockholders; Open the document at this passage
Oct 29
Proxy statement PRE 14A Meeting Dec 18, 2026
Stockholders to vote on another reverse split authorization

Reviva Pharmaceuticals Holdings, Inc. asks stockholders to authorize a reverse stock split ranging from one-for-two (1:2) to one-for-one hundred (1:100) before December 31, 2027.

Read from the first part of this long document
Source passage
To adopt and approve an amendment to the Certificate of Incorporation to effect a reverse stock split of the Company’s issued shares of common stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-one hundred (1:100), at any time prior to December 31, 2027, subject to the Board of Directors’ determination, in its sole discretion, whether or not to implement the reverse stock split and, if so, at what specific ratio within the foregoing range, without further approval or authorization of the Company’s stockholders; Open the document at this passage
Sep 29
Investor event
Lytham Partners Fall 2026 Investor Conference

Reviva Pharmaceuticals Holdings, Inc. said biliroxazine showed sustained schizophrenia efficacy and plans a second phase three study with top-line data in mid-2028 and an NDA filing in end of 2028 or early Q1, 2029.

2025
2024
Showing 1–50 of 170 documents
Key facts CIK 1742927 CUSIP 76152G209 13F (30d) 15 filings 4 filers Visit website Investor relations